Aptevo Therapeutics (APVO) Gains from Investment Securities (2015 - 2016)
Aptevo Therapeutics (APVO) posted Gains from Investment Securities of -$183000.0 for Q4 2016, up 34.64% sequentially from -$280000.0 in Q3 2016, and down 223.65% YoY from $148000.0 in Q1 2016.
Aptevo Therapeutics (APVO) Gains from Investment Securities (2015 - 2016) Analysis & Trends
Aptevo Therapeutics has reported Gains from Investment Securities for 2 years, with the latest figure at -$183000.0 in Q4 2016.
- Quarterly Gains from Investment Securities fell 223.65% year-over-year to -$183000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$444000.0 (changed N/A YoY) and the FY2016 annual result came in at -$444000.0, down 307.48% from the prior year.
- Gains from Investment Securities improved to -$183000.0 in Q4 2016 per APVO's latest filing, from -$280000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $148000.0 in Q4 2015 and troughed at -$280000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -183,000.00 |
| Dec 31, 2016 | -183,000.00 |
| Sep 30, 2016 | -280,000.00 |
| Sep 30, 2016 | -280,000.00 |
| Jun 30, 2016 | 50,000.00 |
| Jun 30, 2016 | 50,000.00 |
| Mar 31, 2016 | -31,000.00 |
| Mar 31, 2016 | -31,000.00 |
| Dec 31, 2015 | 148,000.00 |
| Dec 31, 2015 | 148,000.00 |
| Sep 30, 2015 | -119,000.00 |
| Sep 30, 2015 | -119,000.00 |